BOTHELL, Wash. (AP) ¿ Development-stage biotechnology company Seattle Genetics Inc. said Thursday its third-quarter loss narrowed on higher revenue from partnerships.

The company lost $19.8 million, or 21 cents per share, compared with a loss of $21.8 million, or 27 cents per share, during the same period a year prior. Revenue rose 44 percent to $11.6 million from $8.1 million.

Analysts polled by Thomson Reuters expected a loss of 25 cents per share on revenue of $9.4 million.

The company's key partnership is with Genentech Inc., now part of Roche. The companies are developing potential cancer treatments.

Shares of Seattle Genetics rose 12 cents to close at $9.85.

Copyright 2009 Associated Press. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.

More from Technology

The Good, the Bad, and the Unknowns of AI and Apple Watches

The Good, the Bad, and the Unknowns of AI and Apple Watches

Cramer: Get Your Kids Fluent in Salesforce

Cramer: Get Your Kids Fluent in Salesforce

Amazon Advertising Could Challenge Facebook and Google's Dominance

Amazon Advertising Could Challenge Facebook and Google's Dominance

Biotech and Broadway Come Together to Fight Cancer

Biotech and Broadway Come Together to Fight Cancer

Flashback Friday: Bye Bye FAANG

Flashback Friday: Bye Bye FAANG